AKRO - Akero Therapeutics Inc Stock Price, Fair Value and News

$30.66-0.37 (-1.19%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AKRO Price Action

Last 7 days

-1%

Last 30 days

-0.8%

Last 90 days

17.4%

Trailing 12 Months

90.8%

AKRO RSI Chart

AKRO Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-9.02

Price/Sales (Trailing)

58.77

Price/Free Cashflow

-10.11

AKRO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AKRO Fundamentals

AKRO Revenue

Revenue (TTM)

36.4M

Rev. Growth (Yr)

30.6%

Rev. Growth (Qtr)

-6.75%

AKRO Earnings

Earnings (TTM)

-237.2M

Earnings Growth (Yr)

-83.33%

Earnings Growth (Qtr)

-29.86%

AKRO Profitability

Return on Equity

-32.13%

Return on Assets

-29.02%

Free Cashflow Yield

-9.89%

AKRO Investor Care

Shares Dilution (1Y)

25.29%

Diluted EPS (TTM)

-3.78

AKRO Alerts

3 major insider sales recently.
JANUS HENDERSON GROUP PLC reported owning 10.2% of AKRO [2024-11-14]
Big jump in Revenue (Y/Y)
Big fall in earnings (Y/Y)
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	28.4M	34.0M	36.4M	0
2023	8.9M	14.0M	19.1M	24.2M
2022	0	0	0	3.9M
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Akero Therapeutics Inc

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

CEO	Dr. Andrew Cheng M.D., Ph.D.
WEBSITE	akerotx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	44

Akero Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Akero Therapeutics Inc? What does AKRO stand for in stocks?

AKRO is the stock ticker symbol of Akero Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akero Therapeutics Inc (AKRO)?

As of Wed Nov 20 2024, market cap of Akero Therapeutics Inc is 2.14 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKRO stock?

You can check AKRO's fair value in chart for subscribers.

Is Akero Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AKRO is over valued or under valued. Whether Akero Therapeutics Inc is cheap or expensive depends on the assumptions which impact Akero Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKRO.

What is Akero Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, AKRO's PE ratio (Price to Earnings) is -9.02 and Price to Sales (PS) ratio is 58.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKRO PE ratio will change depending on the future growth rate expectations of investors.